VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

SOHO 2022 | The need for disease-modifying agents in PV to prevent disease progression

Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, highlights the need to find a therapeutic strategy that allows changing the disease course in patients with polycythemia vera (PV) in order to prevent disease progression and improve patient outcomes, commenting on recent data on ropeginterferon alfa-2b. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter